

(21) Application No: **2402730.2**
 (22) Date of Filing: **11.08.2022**
 Date Lodged: **27.02.2024**
 (30) Priority Data:
 (31) **63232409** (32) **12.08.2021** (33) **US**
 (86) International Application Data:
PCT/US2022/040092 En 11.08.2022
 (87) International Publication Data:
WO2023/018891 En 16.02.2023

(51) INT CL:
C07C 317/28 (2006.01) **A61P 17/00** (2006.01)
C07D 295/15 (2006.01) **A61P 17/02** (2006.01)
A61Q 19/00 (2006.01)
 (56) Documents Cited:
WO 2019/060719 A1 **WO 2017/066552 A1**
US 20090306207 A1
Atanaska et al, "Identification of Rigosertib for the Treatment of Recessive...", pg. 3384-3391, Clinical Cancer Research
Prasad et al, "ON 01910.Na (riosertib) inhibits P13K/Akt pathway & activities..." pg 79388-79400, Oncotarget.
 (58) Field of Search:
 INT CL **A61P, A61Q, C07C**
 Other: **PatBase, Google Patents, Google, Pub Chem Compound**

(71) Applicant(s):
Onconova Therapeutics, Inc.
12 Penns Trail, Newtown 18940, Pennsylvania,
United States of America
 (72) Inventor(s):
Steven Fruchtman
Matthew Parris
 (74) Agent and/or Address for Service:
Avidity IP
Broers Building, Hauser Forum, 21 J J Thomson Ave,
CAMBRIDGE, Cambridgeshire, CB3 0FA,
United Kingdom

(54) Title of the Invention: **Methods and compositions for treating cancer**
 Abstract Title: **Methods and compositions for treating cancer**

(57) Disclosed herein is a method of treating a squamous cell carcinoma (SCC), a SCC associated with a disease, for example, recessive dystrophic epidermolysis bullosa (RDEB). The method of the disclosure describes administering a therapeutically-effective amount of (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid, or a pharmaceutically-acceptable salt or zwitterion thereof, and derivatives thereof.




FIG. 1